Literature DB >> 35840728

Early treatment is a lifeline for infants with SMA.

Charlotte J Sumner1,2, Thomas O Crawford3,4.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35840728     DOI: 10.1038/s41591-022-01889-x

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   87.241


× No keyword cloud information.
  2 in total

1.  Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.

Authors:  Kevin A Strauss; Michelle A Farrar; Francesco Muntoni; Kayoko Saito; Jerry R Mendell; Laurent Servais; Hugh J McMillan; Richard S Finkel; Kathryn J Swoboda; Jennifer M Kwon; Craig M Zaidman; Claudia A Chiriboga; Susan T Iannaccone; Jena M Krueger; Julie A Parsons; Perry B Shieh; Sarah Kavanagh; Melissa Wigderson; Sitra Tauscher-Wisniewski; Bryan E McGill; Thomas A Macek
Journal:  Nat Med       Date:  2022-06-17       Impact factor: 87.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.